RxDoctor Payments Data

Watcoun-Nchinda Pisoh, MD

Gastroenterology · Carrollton, GANPI 1568759512

Payments from drug & device makers

$2,427in general payments, 2019–2025

Across 117 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$607
  • AbbVie$411
  • Sanofi$179
  • Phathom Pharmaceuticals, Inc.$168
  • Takeda Pharmaceuticals U.S.A., Inc.$132
  • Endogastric Solutions, Inc$127
  • plus $804 from 17 others

What the payments were for

  • Food & beverage$2,427100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,427 in reported general payments places this provider in the 35th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$115,671
Medicare patients
391
Services billed
804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin25$79,951
LinzessLinaclotide106$63,328
ZenpepLipase/Protease/Amylase18$28,871
VoqueznaVonoprazan Fumarate22$14,056
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates142$9,760
MotegrityPrucalopride Succinate14$7,306
Pantoprazole Sodium285$2,142
Mesalamine15$2,006
Colestipol Hcl39$1,774
Sucralfate16$1,098
CholestyramineCholestyramine (With Sugar)11$868
Lactulose17$493
Mirtazapine22$442
Esomeprazole Magnesium21$432
Famotidine49$415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$607$79,95125 claims
AbbVieLinzess$411$63,328106 claims
Phathom Pharmaceuticals, Inc.Voquezna$168$14,05622 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$132$7,30614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Carrollton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →